News

US FDA approves Gilead's twice-yearly injection for HIV prevention
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
Long-acting HIV prevention drug from Gilead wins FDA approval. Will it get to the people who need it?
The drug is groundbreaking, potentially eliminating the need for a long-sought-after HIV vaccine. In her own words: Anne ...
Agence France-Presse on MSN2d
US approves Gilead's twice-yearly injection to prevent HIV
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.
The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who ...
Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option
Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...
GlobalData on MSN1d
Gilead Sciences’ Yeztugo receives approval from US FDA for HIV
The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a ...
The FDA Just Approved a Long-Lasting Injection to Prevent HIV
Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...
Public Broadcasting Service (PBS)6h
6 things to know about lenacapavir, what experts call a ‘wonder drug’ for preventing HIV
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
This twice-a-year shot to prevent HIV could stop transmission — if people can get it
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...
FDA approves first twice-yearly injection that prevents HIV infection
The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.
Fierce Pharma2d
FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...